The use of i. v. bisphosphonate in pregnancy-associated osteoporosis--case study

Exp Clin Endocrinol Diabetes. 2007 Feb;115(2):139-42. doi: 10.1055/s-2007-967091.

Abstract

Objective: Diagnosis of pregnancy-associated osteoporosis is often delayed and therapeutic interventions insufficient.

Study design: A 28-year-old patient (BMI=18.6) with no additional risks for osteoporosis experienced acute lumbosacral pain two months postpartum, while lactating. After conservative therapy, thoracic and lumbar spine were X-rayed: severe pregnancy-associated osteoporosis with vertebral fractures was diagnosed. 2-year treatment with i. v. bisphosphonate ibandronate was initiated (2 mg every 3 months) and calcium and vitamin D supplementation.

Results: Rapid improvement was observed. Conclusion: In cases with multiple fractures i. v. bisphosphonate leads to substantial decrease of symptoms and further fractures and significant increase of bone mass density (BMD).

Conclusion: In severe cases of pregnancy-associated osteoporosis with multiple fractures i. v. biphosphonate therapy leads to a decrease of symptoms and fracture risk and an increase of bone mass density (BMD).

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Bone Density
  • Bone Density Conservation Agents / administration & dosage
  • Diphosphonates / administration & dosage
  • Diphosphonates / therapeutic use*
  • Female
  • Humans
  • Injections, Intravenous
  • Osteoporosis / diagnostic imaging
  • Osteoporosis / drug therapy*
  • Osteoporosis / etiology*
  • Pregnancy
  • Pregnancy Complications / drug therapy
  • Radiography

Substances

  • Bone Density Conservation Agents
  • Diphosphonates